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Context: Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant hereditary 
disease caused by the loss of function of the MEN1 gene, a tumor-suppressor gene that encodes 
the protein menin. It is characterized by the occurrence of primary hyperparathyroidism (pHPT), 
duodenopancreatic neuroendocrine tumors (dpNET), pituitary tumors (PIT), adrenal adenomas, 
and bronchopulmonary (bp-NET), thymic, and gastric neuroendocrine tumors. More insight into 
factors influencing the age-related penetrance of MEN1 manifestations could provide clues for 
more personalized screening programs.
Objective: To investigate whether genetic anticipation plays a role in the largest known MEN1 
families in the Netherlands.
Methods: All Dutch MEN1 families with ≥ 10 affected members in ≥ 2 successive generations 
were identified. Age at detection of the different MEN1-related manifestations were compared 
among generations using regression analyses adjusted for competing risks. To correct for the 
beneficial effect of being under surveillance, manifestations occurring during surveillance were 
also separately compared.
Results: A total of 152 MEN1 patients from 10 families were included. A significantly decreased 
age at detection of pHPT, dpNET, PIT, and bp-NET was found in successive generations 
(P < 0.0001). Adjusted analyses led to the same results.
Conclusions: These results suggest the presence of genetic anticipation. However, due to a risk 
of residual bias, the results must be interpreted with caution. After independent validation 
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in other cohorts and further translational research investigating the molecular mechanisms 
explaining this phenomenon in MEN1, the results might add to future, more personalized, 
screening protocols and earlier screening for future generations of MEN1 patients. (J Clin 
Endocrinol Metab 105: 1–10, 2020)
Freeform/Key Words:  age of onset, genetic anticipation, multiple endocrine neoplasia type 1, 
surveillance
Multiple Endocrine Neoplasia type 1 (MEN1) is a rare hereditary disease caused by loss of func-
tion of the MEN1 gene. The MEN1 gene is a tumor 
suppressor gene that encodes the protein menin. It has 
an estimated prevalence of 2–10 per 100000 and is in-
herited in an autosomal dominant pattern (1). Although 
a wide variety of manifestations have been described, 
most MEN1 patients suffer from (1) primary hyperpara-
thyroidism (pHPT) (90–95%), (2) duodenopancreatic 
neuroendocrine tumor (dpNET) (35–75%), (3) anterior 
pituitary tumors (PIT) (20–65%), (4) adrenal aden-
omas (ADR) (11–35%), and (5) bronchopulmonary 
(bp-NET), thymic (th-NET), and gastric neuroendo-
crine tumors (20–30%) (2, 3). MEN1 mutations have 
a high penetrance, and patients with MEN1 suffer from 
high morbidity and a decreased life expectancy (4). In 
particular, th-NET and pancreatic NET are main causes 
of MEN1-related death (4, 5).
In order to detect MEN1 manifestations in an early 
stage, periodic screening of MEN1 patients is advised. 
The present clinical practice guidelines advise to start 
screening for a number of manifestations at the age of 
5 in all MEN1 mutation carriers, and to expand the 
screening with age (6). Despite numerous efforts, no 
direct genotype–phenotype correlation has been found 
to date (7). Although minor familial clustering of spe-
cific tumors has been described (8), in general both a 
considerable phenotypic variability of manifestations, 
as well as variable age at diagnosis, have been reported 
(7). More insight into factors influencing the age-related 
penetrance of MEN1 manifestations could provide clues 
for more personalized screening programs for MEN1 
mutation carriers, potentially leading to a decrease in 
patient (and parental) burden, as well as lower health 
care costs.
Genetic anticipation refers to the phenomenon of 
decreased age of disease onset or an increased disease 
severity in successive generations. It is best known in 
neuropsychiatric diseases such as Huntington’s disease 
and myotonic dystrophy. In these diseases, trinucleotide 
repeat expansions (“growing genes”) are responsible for 
the phenotype of genetic anticipation, as the length of 
the repeat is transmitted in an unstable way and can 
be influenced by the parental origin (9). More recently, 
anticipation was also described in forms of heritable 
cancer such as dyskeratosis congenita, Lynch Syndrome, 
Li-Fraumeni syndrome, von Hippel-Lindau syndrome, 
and hereditary breast and ovarian cancer syndrome 
(10–14). In these syndromes the genetic defect is trans-
mitted without alterations. Partly due to the lack of gen-
erally accepted explanatory biological mechanism and 
a high risk of bias in this field of research, some pub-
lications suggested this observation to be the result of 
different forms of bias (15–17). To our knowledge, data 
about genetic anticipation within MEN1 families are 
limited to 1 study, describing a MEN1 family of 5 gener-
ations with clinical expression suggestive of anticipation 
(18). The aim of this nationwide study is to investigate 
whether genetic anticipation plays a role in the largest 
known MEN1 families in the Netherlands.
Methods
Patient selection
Since the discovery of the MEN1 gene in 1997 until re-
cently, all genetic testing for MEN1 gene abnormalities in the 
Netherlands has been performed centrally at the University 
Medical Center Utrecht. All potential Dutch MEN1 patients 
and mutation carriers referred for genetic testing between 
January 1998 and December 2017 were identified. Pedigree 
information was retrieved from medical records and checked 
using the Dutch Municipal Resident Registration. Mutation-
positive MEN1 families were selected if these families com-
prised at least 10 affected members in 2 or more successive 
generations.
Retrieval of clinical information
Clinical information about affected family members 
was obtained using the national MEN1 database of the 
Dutch MEN1 study group (DMSG). This database con-
tains longitudinally collected clinical information of pa-
tients ≥ 16 years of age at the end of 2017 and treated at 1 
of the Dutch university medical centers between 1990 and 
2017. The study cohort includes ≥ 90% of the total Dutch 
MEN1 population. Data of all the patients were collected 
from every quarter of every available year of follow-up, 
from 1990 to 2017. Furthermore, data concerning the oc-
currence of MEN1-related manifestations before 1990 and 
before 16 years of age were included as well. Detailed in-
formation on the DMSG database methods have been de-
scribed previously (19).
Patients deceased before 1990, < 16  years of age on 
December 31, 2017, or patients whose clinical or pedigree in-
formation was lacking were excluded from this study.
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Definitions of MEN1 manifestations
In order to determine the exact prevalence and time of diag-
nosis of an MEN1-related manifestation, the following defin-
itions of MEN1-related manifestations were used: pHPT was 
defined as elevated calcium combined with a normal to ele-
vated PTH level in 2 consecutive measurements; dpNET was 
diagnosed based on tissue examination or—if not available—
gastroduodenoscopy (duodenum NET) or ≥ 1 abnormality on 
imaging studies in at least 2 successive investigations (pancreas 
NET); pituitary, adrenal, and bp-NET tumors were labeled as 
such based on histology or—if not available—imaging studies 
suggestive of these specific tumors in at least 2 successive in-
vestigations. Thymic and gastric NET was diagnosed on a 
histological basis only. Details for the reference standards of 
MEN1-related manifestations have been described previously 
(19, 20). 
Statistical analysis
Patients were ranked from oldest to youngest generation, 
based on their position within the family pedigree. Clinical 
characteristics were reported as mean and standard deviation 
or median with range based on the distribution of data. Time-
to-event methods were used to evaluate the age at detection 
of MEN1-related manifestations. The patients’ lifetimes from 
birth until death, lost to follow-up, or the end of follow-up 
(December 31, 2017)  were included for analysis. The 
age-related penetrance of MEN1-related manifestations were 
analyzed using cumulative incidence functions, accounting for 
death as a competing risk. Generations were compared using 
Gray’s test. Additionally, the effect of generation on phenotype 
was evaluated using proportional subdistribution hazards re-
gression models, as described by Fine and Gray (21–23). 
However, these results may overestimate a possible anticipa-
tion effect, since these analyses do not take into the account 
the benefits of surveillance programs: with regular laboratory 
tests and imaging studies, tumors are more likely to be de-
tected early in life. Since older generations may have profited 
less from these programs, and manifestations in patients from 
older generations were more frequently detected because of 
symptoms rather than presymptomatic screening, results may 
be distorted. In an attempt to reduce this bias, separate time-
to-event analyses were conducted focusing on MEN1-related 
manifestations occurring in patients within the timeframe that 
they were under surveillance. In this manner we attempted 
to reduce the risk of detection bias, since these manifest-
ations were detected in a comparable manner (eg, early diag-
nosis when being under surveillance) across all generations. 
Statistical significance was set at a 2-sided P < 0.05. Analyses 
were performed using IBM SPSS 25.0 and R version 3.4.1.
Results
A total of 10 families were included, comprising 157 
MEN1 patients from the DMSG database ≥ 16 years of 
age at the end of 2017. Five patients were excluded due 
to insufficient pedigree information. The study popula-
tion consisted of 80 females (52.6%) with a median age 
at the end of follow-up (December 31, 2017, or death) 
of 49 years (range 19–84 years). Genetic analysis was 
performed in 134 patients (88%), and a mutation (or 
affected allele) was found in all of these cases. Main 
features of the 10 families are described in Table  1. 
The number of affected family members ranged from 
11 to 29 per family. A  total of 137 affected members 
(90.1%) showed 1 or more MEN1-related manifest-
ation during follow-up. Primary hyperparathyroidism 
showed the highest penetrance (121 patients, 80%), 
th-NET the lowest (2 patients, 1%). Two families 
showed an unusually low penetrance of MEN1 mani-
festations: (1) family 6 with mutation c.545T > C(p.
Leu182Pro) in exon 3, and (2) family 10 with mutation 
c.670-6C > G(p.?) in intron 3. The latter family was re-
ported in an earlier study (24).
Age at detection of MEN1 manifestations
A total of 42 patients (28%) were labeled as first 
generation. The second generation included 68 patients 
(45%), the third generation included 40 patients (26%), 
and 2 patients (1%) were identified as fourth gener-
ation family members. In all MEN1-related manifest-
ations, the median age at detection was highest in the 
first generation and lowest in the last (third and fourth) 
generations. The difference in median age at detection 
between the first and last generation ranged between 
8 years (th-NET) and 40 years (dp-NET). The median 
age at detection of the first encountered manifestation 
was 46 (range: 21–73 years) in the first generation, com-
pared with 14 (range: 11–17 years) in the youngest gen-
eration. More detailed results are displayed in Table 2.
Time-to-event analyses showed a significantly higher 
age-related penetrance of pHPT, dpNET, PIT, and 
bp-NET in successive generations (Fig.  1). Additional 
analyses investigating the age at detection of bp-NET 
based on pathology results alone (n = 13) showed 
similar results (data not shown). Although younger gen-
erations also tend to experience adrenal tumors earlier 
in life, this trend did not reach statistical significance 
(P = 0.17). Furthermore, patients from younger gen-
erations encountered their first MEN1-related tumor 
significantly earlier in life. When only focusing on mani-
festations that occurred under surveillance, the results 
were the same (Fig. 2). Results from the proportional 
subdistribution hazards regression models demonstrated 
evidence of genetic anticipation in MEN1-related mani-
festations as well. More details are provided in Table 3.
In order to investigate potential interference, add-
itional analyses were carried out excluding the 2 fam-
ilies with a low penetrance of disease (families 6 and 
10), which showed similar results (data not shown). 
Furthermore, supplementary analyses only com-
paring the second and third generations demonstrated 
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comparable evidence of genetic anticipation as well 
(data not shown).
The occurrence of metastatic disease occurring in pa-
tients during their time under surveillance—as a proxy 
for disease severity—was equal across generations (data 
not shown).
Discussion
Results from this first nationwide and multifamily study 
on genetic anticipation in MEN1 showed that mani-
festations occurred significantly earlier in the lives of 
patients from successive generations. Even with the 
adjustments for the beneficial effect of surveillance 
programs, our results suggested the presence of gen-
etic anticipation in MEN1. Since metastasis occurred 
equally across generations there was no indication of 
increased disease severity in successive generations.
The study included a cohort of the largest Dutch 
MEN1 families selected from all referrals for MEN1 
mutation testing in the Netherlands, making it very un-
likely to have missed any MEN1 family of relevance 
for answering the study questions. We expect patients 
from this cohort to represent the general MEN1 popu-
lation, and we subsequently expect these results to 
be generalizable to other MEN1 families. Clinical in-
formation was obtained using the DMSG database, 
in which extensive follow-up data of MEN1 patients 
was collected quarterly using a predefined protocol. 
Furthermore, possible MEN1 manifestations were in-
terpreted using well-defined criteria. This standardiza-
tion of data makes it possible to accurately investigate 
the natural course of MEN1-related manifestations in 
this population.
It should be noted, however, that studies evaluating 
the possibility of anticipation always suffer from a sig-
nificant risk of bias. Especially in retrospective studies, 
one must be aware of ascertainment bias as a result of 
selection of families: selection of affected parents with 
late onset of disease, selection of affected descendants 
with young onset of disease, and/or selection of cases 
with simultaneous onset in parents and offspring (25, 
26). Our study used predefined inclusion criteria to ana-
lyze MEN1 families regardless of penetrance or age at 
detection in different generations, minimizing the risk of 
this type of bias.
Furthermore, bias can arise from differences in 
follow-up time between generations (so-called “trun-
cation bias”) (27) Older generations have been under 
care for a longer period of time than their offspring and 
generally will not have been followed for the entire “at 
risk” period, which can introduce possible bias.
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In addition, detection bias can occur in multigener-
ational studies as a result of a beneficial effect of sur-
veillance programs for individuals at risk. The use of 
predefined surveillance protocols and well-defined cri-
teria of MEN1 manifestations standardizes follow-up 
for younger generations. However, older generations 
have benefited less from these screening methods, 
introducing a possible delay in diagnosing manifest-
ations compared to younger generations. We attempted 
to reduce this form of bias by conducting separate 
time-to-event analyses that only included manifest-
ations detected during the period of time the patients 
were under surveillance for MEN1.
The effect of different observation periods (time bias) 
must also be taken into account. The improvement of 
diagnostics—such as enhanced imaging techniques with 
higher sensitivity—could have resulted in earlier detec-
tion of MEN1 manifestations in later generations. Also, 
other period-related factors (eg, improvement of medical 
knowledge, change of potential unknown carcinogenics, 
Figure 1. Age-related penetrance of MEN1 manifestations. Due to low penetrance of th-NET and gastric neuroendocrine tumors, these 
manifestations were not included in the analyses. Because of the small sample size of the fourth generation (n = 2), the age-related penetrance of 
MEN1 manifestations of this generation are excluded from this analyses. Abbreviations: 1st, first manifestation; ADR, adrenal adenoma; bp-NET, 
bronchopulmonary neuroendocrine tumor; dpNET, duodenopancreatic neuroendocrine tumor; Gen 1, first generation; Gen 2, second generation; 
Gen 3, third generation; pHPT, primary hyperparathyroidism; PIT, anterior pituitary tumor.
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or other environmental factors) could have influenced 
the age at detection of different MEN1 manifestations. 
However, the average year at detection of dpNET, PIT, 
and bp-NET did not differ much between generations, 
suggesting that time bias was not of great influence on 
these results. As the median year of pHPT and ADR 
diagnosis differed more across generations, the effect 
of improved diagnostics or other observation period-
related factors cannot be ruled out in these cases.
Finally, the low prevalence of specific MEN1 mani-
festations (eg, th-NET and gastric NET) and the small 
sample size of fourth generation family members com-
promise the precision of estimations regarding the age 
at detection of MEN1-related manifestations and the 
possible effect of anticipation. With all these potential 
biases and limitations in mind, conclusions about the 
presence of genetic anticipation in MEN1 must be inter-
preted with caution.
In 1997, Giraud et al implied the possibility of an-
ticipation within MEN1 by describing 1 MEN1 family 
with clinical expression suggestive of this phenom-
enon (18). The second and third generations of this 
Figure 2. Age-related penetrance of MEN1 manifestations during surveillance. Due to low penetrance of th-NET and gastric neuroendocrine 
tumors, these manifestations were not included in the analyses. Because of the small sample size of the fourth generation (n = 2), the age-related 
penetrance of MEN1 manifestations of this generation are excluded from this analyses. Abbreviations: 1st, first manifestation; ADR, adrenal 
adenoma; bp-NET, bronchopulmonary neuroendocrine tumor; dpNET, duodenopancreatic neuroendocrine tumor; Gen 1, first generation; Gen 2, 
second generation; Gen 3, third generation; in FU, in follow-up; pHPT, primary hyperparathyroidism; PIT, anterior pituitary tumor.
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particular family showed no clinical evidence of MEN1 
to date, whereas in the fourth generation 8 members 
were affected (including 2 metastatic th-NET, a case 
of metastatic dpNET, and a spinal ependymoma). All 
5 fifth-generation patients showed at least 1 MEN1-
related manifestation below the age of 22. More re-
cently, intrafamilial correlations and the heritability 
of MEN1 manifestations were investigated in a large 
French cohort of 797 patients. Thevenon et al reported 
significant heritability of 3 MEN1 manifestations (PIT, 
ADR, and th-NET). However, genetic anticipation was 
not a subject of the study (8).
In order to make a valid call on the existence of gen-
etic anticipation in MEN1, both (repeated) conclusive 
observations of decreased age at detection in successive 
generations and a commonly accepted explanatory bio-
logical mechanism are needed. However, little is known 
about the possible molecular mechanisms, which could 
explain anticipation in hereditary cancer syndromes 
like MEN1.
One potential mechanism involves progressive telo-
mere shortening. In 2004, Vulliamy et al found an as-
sociation between clinical anticipation and a significant 
decrease in telomere length in successive generations 
in autosomal dominant dyskeratosis congenita, pos-
sibly owing to haploinsufficiency of the affected gene 
encoding the RNA component of telomerase (TERC) 
(10). This association was also reported in hereditary 
breast cancer syndrome, Li-Fraumeni syndrome, and 
von Hippel Lindau disease (14, 28, 29). In contrast, an 
association study of telomere length and single nucleo-
tide polymorphisms (SNPs) in 43 telomere biology genes 
showed inverse associations between all SNPs included 
in the MEN1 region and telomere length. This suggests 
that a loss of function would result in an increased telo-
mere length, which is in contrast to what one would 
expect (30). However, this assumption has not been in-
vestigated in affected MEN1 patients up to now.
A second hypothesis to explain anticipation has been 
suggested in Lynch syndrome and is based on the pro-
gressive accumulation of germline mutations prior to 
the loss of heterozygosity (31). Possibly (low) levels of 
microsatellite instability are present in the germ cells of 
patients with Lynch syndrome, passing on mutant alleles 
to their offspring. Of course, the molecular functions of 
mismatch repair genes associated with Lynch syndrome 
(MSH2, MLH1, MSH6, and PMS2) are incomparable 
to the functions of menin, which—although not en-
tirely unraveled yet—appear to concentrate on gene ex-
pression regulation (32). Therefore, it is very doubtful 
whether this hypothesis is applicable to MEN1. To our 
knowledge, impairment of menin function before loss of 
heterozygosity has not been investigated to date.
A third mechanism for anticipation has been pro-
posed in Li-Fraumeni syndrome. It is suggested that 
anticipation is caused by the accumulation of DNA 
copy number variations in the context of TP53 
haploinsufficiency (33). Others have proposed an 
Table 3. Regression modelsa.
Manifestationa  
(During Surveillance) Generation Number
Hazard Ratio  
(Generation)b Standard Error Wald P-value
Primary hyperparathyroidism First 1.00b – <0.0005
Second 1.62 0.666
Third 11.75 0.597
Pancreatic- and duodenal NET First 1.00b – <0.0005
Second 2.07 0.249
Third 4.87 0.375
Pituitary adenoma First 1.00b – <0.0005
Second 1.21 0.398
Third 6.53 0.388
Adrenal tumor First 1.00b – 0.0076
Second 2.14 0.340
Third 4.90 0.587
Bronchopulmonary NET First 1.00b – <0.0005
Second 3.29 0.416
Third 16.00 0.533
First manifestation First 1.00b – <0.0005
Second 3.38 0.754
Third 18.43 0.718
Abbreviation: NET, neuroendocrine tumor.
aProportional subdistribution hazards regression models (described in Fine and Gray (21)), assessing the effect of generation (explanatory covariate) 
on the occurrence of different MEN1-related manifestations diagnosed during the surveillance period (event of interest). Death and manifestations 
diagnosed before the start of surveillance are defined as competing risks. The occurrence of gastric NET and th-NET are not modeled due to the low 
penetrance of these manifestations. Because of the small sample size of the fourth generation (n = 2), this generation is excluded from this analyses.
bThe subdistribution hazard of cumulative incidence function. The first generation is defined as the reference generation.
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alternative model in which anticipation could be ex-
plained by the inheritance of specific risk-increasing fac-
tors from the noncarrier parent (34). Studies to explore 
these theories in MEN1 have not been performed yet.
In conclusion, results from this study showed a de-
creased age at detection of MEN1 manifestations in suc-
cessive generations, suggesting the presence of genetic 
anticipation. However, despite our efforts, it is not pos-
sible to draw firm conclusions from these analyses due 
to the potential risk of residual bias. Our results require 
confirmation in other large population-based MEN1 co-
horts with long-term follow-up to determine the true role 
of genetic anticipation in MEN1 syndrome. Furthermore, 
translational research is needed to investigate molecular 
mechanisms explaining this phenomenon of anticipation 
in MEN1. The demonstration of genetic anticipation in 
MEN1 would provide the opportunity for more personal-
ized screening protocols, with the possibility of screening 
at a younger age in future generations of MEN1 patients.
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